Home | Welcome to Contract Pharma   
Last Updated Saturday, May 18 2013
Print RSS Feed

Breaking News

Related Searches: Collaborations & Alliances •
EPIX Earns GSK Milestone

August 14, 2007
EPIX Pharmaceuticals, Inc. has earned a $3 million milestone payment under its collaboration with GlaxoSmithKline related to the first of three discovery stage programs. EPIX has identified three lead candidates that will move forward into lead optim…  Read More »
Parexel Consulting

August 14, 2007
Dr. Hans Van Bronswijk has been appointed to the position of principal consultant for Parexel Consulting in its European Drug Development Practice. In this role, Dr. Van Bronswijk will advise clients on all aspects of clinical development and regulat…  Read More »
AAPS

August 13, 2007
Patrick P. DeLuca, Ph.D., professor in the faculty of Pharmaceutical Sciences at the University of Kentucky College of Pharmacy, has been elected to serve as president-elect of the American Association of Pharmaceutical Scientists (AAPS), based in Ar…  Read More »
Roche Files IND for Genmab Antibody

August 13, 2007
Roche has filed an IND with the FDA for a Genmab antibody developed under the companies' collaboration. Genmab will receive a milestone payment from Roche. Under the agreement with Roche, Genmab uses its antibody expertise and development capabi…  Read More »
Kendle

August 13, 2007
Timothy Forsey, Ph.D. has been appointed principal regulatory affairs consultant at Kendle, specializing in providing regulatory affairs guidance to biotechnology customers. He will be based in the Ely, Cambridgeshire office in England and will work…  Read More »
ImClone Systems

August 10, 2007
John H. Johnson, formerly of Johnson & Johnson, has been named chief executive officer, ImClone Systems, effective August 27th. Mr. Johnson has more than two decades of executive and operational management experience in the biopharmaceutical and…  Read More »
Biogen Idec

August 10, 2007
Paul Clancy has been appointed executive vice president and chief financial officer, Biogen Idec. He reports to James C. Mullen, the company's chief executive officer, and most recently served as senior vice president of finance, responsible for lead…  Read More »
Bilcare Invests in Facility Upgrades

August 10, 2007
Bilcare has begun a capital investment project in an effort to enhance its global footprint and increase capacity and capabilities. The company is upgrading its packaging, storage and distribution facilities at its U.S. headquarters in Phoenixville,…  Read More »
Wyeth, Solvay's Bifeprunox "Not Approvable"

August 10, 2007
Wyeth and Solvay Pharmaceuticals received a "not approvable" letter from the FDA in response to the NDA for bifeprunox, an atypical antipsychotic for the acute treatment of schizophrenia, as well as the maintenance of stable adult patients.…  Read More »
FDA Says New Advair Dose Not Approvable

August 9, 2007
The FDA has issued a "not approvable" letter for GlaxoSmithKline's sNDA for the 500/50 strength of Advair Diskus for the treatment of chronic obstructive pulmonary disease (COPD). Specifically, the agency questioned how the new dose compare…  Read More »
Financial Report: BASi

August 9, 2007
BASi 3Q Revenues: $12.6 million (26%) 3Q Earnings: $449,000 (loss of $1.8 million 3Q2006) YTD Revenues: $34.8 million (+8%) YTD Earnings: $1.1 million (loss of $1.9 million YTD2006) Comments: Revenue growth was driven by a $2.7…  Read More »
Financial Report: Abraxis BioScience

August 9, 2007
Abraxis BioScience, Inc. 2Q Revenue: $242.5 million (+51%) 2Q Earnings: $23.1 (loss of $90.8 million 2Q2006) YTD Revenues: $454.7 million (+49%) YTD Earnings: $34.2 (loss of $88.9 million YTD2006) Comments: In the quarter, Abraxan…  Read More »
Neuromed, Merck Discontinue Pain Drug Candidate

August 8, 2007
Merck and Neuromed Pharmaceuticals have discontinued development of NMED-160 (also known as MK-6721), a Phase II compound for the treatment of chronic pain. Their joint research collaboration will continue to evaluate other therapeutic candidates.…  Read More »
Galapagos, AZ Enter 3rd Discovery Pact

August 8, 2007
Galapagos NV's service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca, under which BioFocus will perform medicinal chemistry, computational chemistry and support biology and ADMET services for AZ's infect…  Read More »
Financial Report: Hospira

August 8, 2007
Hospira 2Q Revenues: $869.4 million (+29.5) 2Q Earnings: $30.7 million (-43%) YTD Revenues: $1.7 billion (+24%) YTD Earnings: $1.3 million (-99%) Comments: Pharmaceutical contract manufacturing revenues were $36.9 million in the q…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: